Predictmedix (CSE: PMED- OTCQB: PMEDF) CEO Dr. Rahul Kushwah shared with Proactive’s Steve Darling, the company has made an acquisition of a company called Symp2Pass. This company reported revenue of 2.27 million dollars last year.
Kushwah telling Proactive Symp2Pass is one of the first end-to-end advanced touchless health and wellness testing solution that currently provides advanced COVID-19 screening coupled with geolocation mapping. That includes integration capabilities with other IoT products such as RFID bracelets and scanners.